The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment.

[1]  M. Mehta,et al.  Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. , 2008, International journal of radiation oncology, biology, physics.

[2]  Jian-Ming Zhu,et al.  Quantitative Magnetic Resonance Spectroscopy Reveals a Potential Relationship between Radiation-Induced Changes in Rat Brain Metabolites and Cognitive Impairment , 2007, Radiation research.

[3]  D. Diz,et al.  Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. , 2007, American journal of physiology. Heart and circulatory physiology.

[4]  S. Ahmed,et al.  Capillary loss precedes the cognitive impairment induced by fractionated whole-brain irradiation: A potential rat model of vascular dementia , 2007, Journal of the Neurological Sciences.

[5]  F. Hsu,et al.  Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. , 2007, International journal of radiation oncology, biology, physics.

[6]  Stephen L. Brown,et al.  Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time , 2007, Journal of Neuro-Oncology.

[7]  S. Bentzen.  Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology , 2006, Nature Reviews Cancer.

[8]  E. Shaw,et al.  Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Brown,et al.  Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Diz,et al.  Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. , 2006, International journal of radiation oncology, biology, physics.

[11]  A. Ribeiro.  Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. , 2006, Current medical research and opinion.

[12]  D. Moody,et al.  Vascular Damage after Fractionated Whole-Brain Irradiation in Rats , 2005, Radiation research.

[13]  S. J. Martin,et al.  Interrogating rodents regarding their object and spatial memory , 2005, Current Opinion in Neurobiology.

[14]  I. Stella,et al.  Protective effect of the inhibition of the renin–angiotensin system on aging , 2005, Regulatory Peptides.

[15]  D. Diz,et al.  Divergent Regulation of Circulating and Intrarenal Renin-Angiotensin Systems in Response to Long-Term Blockade , 2005, American Journal of Nephrology.

[16]  C. N. Coleman,et al.  Modulation of Radiation Injury , 2004, Science.

[17]  Weiling Zhao,et al.  Chronic oxidative stress and radiation‐induced late normal tissue injury: a review , 2004, International journal of radiation biology.

[18]  John W. Wright,et al.  The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory , 2004, Progress in Neurobiology.

[19]  Stephen L. Brown,et al.  Modification of Radiation Injury by Ramipril, Inhibitor of Angiotensin-Converting Enzyme, on Optic Neuropathy in the Rat , 2004, Radiation research.

[20]  R. Davisson.  Physiological genomic analysis of the brain renin-angiotensin system. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[21]  C. May,et al.  The brain renin-angiotensin system: location and physiological roles. , 2003, The international journal of biochemistry & cell biology.

[22]  E. Cohen,et al.  ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. , 2003, Current pharmaceutical design.

[23]  W. Small,et al.  Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. , 2003, Current pharmaceutical design.

[24]  T. van Groen,et al.  Age‐Related Decline in Spatial Learning and Memory: Attenuation by Captopril , 2003, Clinical and experimental hypertension.

[25]  T. Unger,et al.  The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers , 2002, Journal of Human Hypertension.

[26]  E. Cohen,et al.  The renin-angiotensin system in experimental radiation nephropathy. , 2002, The Journal of laboratory and clinical medicine.

[27]  P. Gard.  The role of angiotensin II in cognition and behaviour. , 2002, European journal of pharmacology.

[28]  G. Salvo,et al.  Does the Angiotensin II Receptor Antagonist Losartan Improve Cognitive Function? , 2002, Drugs & aging.

[29]  D. Diz,et al.  Differential actions of renal ischemic injury on the intrarenal angiotensin system. , 2000, American journal of physiology. Renal physiology.

[30]  J. M. Taylor,et al.  Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. , 2000, International journal of radiation biology.

[31]  D. Diz,et al.  Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. , 1998, Hypertension.

[32]  A. Ennaceur,et al.  A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory , 1992, Behavioural Brain Research.

[33]  A. Molteni,et al.  Captopril reduces collagen and mast cell accumulation in irradiated rat lung. , 1990, International journal of radiation oncology, biology, physics.

[34]  J. Delacour,et al.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data , 1988, Behavioural Brain Research.